Genetically engineered biomimetic ATP-responsive nanozyme for the treatment of cardiac fibrosis.

IF 10.6 1区生物学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Journal of Nanobiotechnology Pub Date : 2025-01-09 DOI:10.1186/s12951-024-03083-2

Xueli Zhao, Yuze Qin, Bowen Li, Yue Wang, Jiao Liu, Bo Wang, Jia Zhao, Jiaqi Yin, Lanlan Zhang, Jing Li, Junzhe Huang, Kun Chen, Liwen Liu, Yuanming Wu

{"title":"Genetically engineered biomimetic ATP-responsive nanozyme for the treatment of cardiac fibrosis.","authors":"Xueli Zhao, Yuze Qin, Bowen Li, Yue Wang, Jiao Liu, Bo Wang, Jia Zhao, Jiaqi Yin, Lanlan Zhang, Jing Li, Junzhe Huang, Kun Chen, Liwen Liu, Yuanming Wu","doi":"10.1186/s12951-024-03083-2","DOIUrl":null,"url":null,"abstract":"Background: Cardiac fibrosis plays a critical role in the progression of various forms of heart disease, significantly increasing the risk of sudden cardiac death. However, currently, there are no therapeutic strategies available to prevent the onset of cardiac fibrosis.Methods and results: Here, biomimetic ATP-responsive nanozymes based on genetically engineered cell membranes are adapted to specifically recognize activated cardiac fibroblasts (CFs) for the treatment of cardiac fibrosis. By fusing the anti-FAP CAR genetically engineered cell membrane to zeolitic imidazole frameworks-90 (zif-90) cores loaded with antioxidant nanozymes CeO2 and siCTGF (siRNA targeting CTGF), these nanoparticles, called FM@zif-90/Ce/siR NPs, are demonstrated to effectively reduce the accumulation of myofibroblasts and the formation of fibrotic tissue, while restoring cardiac function.Conclusions: These findings demonstrate that the combination of CeO2 and siCTGF has a beneficial curative effect on cardiac fibrosis, with significant translational potential.","PeriodicalId":16383,"journal":{"name":"Journal of Nanobiotechnology","volume":"23 1","pages":"10"},"PeriodicalIF":10.6000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11715444/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nanobiotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1186/s12951-024-03083-2","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Cardiac fibrosis plays a critical role in the progression of various forms of heart disease, significantly increasing the risk of sudden cardiac death. However, currently, there are no therapeutic strategies available to prevent the onset of cardiac fibrosis.

Methods and results: Here, biomimetic ATP-responsive nanozymes based on genetically engineered cell membranes are adapted to specifically recognize activated cardiac fibroblasts (CFs) for the treatment of cardiac fibrosis. By fusing the anti-FAP CAR genetically engineered cell membrane to zeolitic imidazole frameworks-90 (zif-90) cores loaded with antioxidant nanozymes CeO₂ and siCTGF (siRNA targeting CTGF), these nanoparticles, called FM@zif-90/Ce/siR NPs, are demonstrated to effectively reduce the accumulation of myofibroblasts and the formation of fibrotic tissue, while restoring cardiac function.

Conclusions: These findings demonstrate that the combination of CeO₂ and siCTGF has a beneficial curative effect on cardiac fibrosis, with significant translational potential.

查看原文本刊更多论文

用于心脏纤维化治疗的基因工程仿生atp反应纳米酶。

背景：心脏纤维化在各种心脏病的进展中起着关键作用，显著增加心源性猝死的风险。然而，目前还没有有效的治疗策略来预防心脏纤维化的发生。方法和结果：在这里，基于基因工程细胞膜的仿生atp反应纳米酶被适应于特异性识别活化的心脏成纤维细胞（CFs），用于治疗心脏纤维化。通过将抗fap CAR基因工程细胞膜融合到含有抗氧化纳米酶CeO2和siCTGF（靶向CTGF的siRNA）的分子式米唑框架-90 （zif-90）内核中，这些被称为FM@zif-90/Ce/siR NPs的纳米颗粒被证明可以有效减少肌成纤维细胞的积累和纤维化组织的形成，同时恢复心脏功能。结论：CeO2与siCTGF联合治疗心脏纤维化具有良好的疗效，具有显著的转化潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Nanobiotechnology BIOTECHNOLOGY & APPLIED MICROBIOLOGY-NANOSCIENCE & NANOTECHNOLOGY

CiteScore

13.90

自引率

4.90%

发文量

493

审稿时长

16 weeks

期刊介绍： Journal of Nanobiotechnology is an open access peer-reviewed journal communicating scientific and technological advances in the fields of medicine and biology, with an emphasis in their interface with nanoscale sciences. The journal provides biomedical scientists and the international biotechnology business community with the latest developments in the growing field of Nanobiotechnology.